Table 3 Lecture topics provided for each lecture theme in the survey
From: An evaluation of pharmacology curricula in Australian science and health-related degree programs
Lecture theme | Lecture topic |
|---|---|
Pharmacodynamics | Introduction to Pharmacology/Drug Action |
| Â | Drug-receptor interactions |
| Â | Drug targets (receptors, enzymes, transporters) |
| Â | Quantitation of drug action/Measurement in Pharmacology |
| Â | Agonism/Agonists |
| Â | Antagonism/Antagonists |
| Â | Models of drug action/Pharmacodynamics |
| Â | Determinants of drug potency/effectiveness |
| Â | Physicochemical properties of drugs |
| Â | Receptors (ion channels, GPCRs, intracellular receptors) |
| Â | Intracellular signalling/Signal transduction |
| Â | Transporters |
| Â | Desensitisation/Tachyphylaxis |
Pharmacokinetics | Drug absorption and distribution |
| Â | Drug metabolism |
| Â | Drug excretion |
| Â | Pharmacokinetics applied |
| Â | Pharmacokinetics calculations |
| Â | Effects of age/renal disease/liver disease on pharmacokinetics |
| Â | Pharmacogenetics/Pharmacogenomics |
Xenobiotic metabolism and toxicology | Xenobiotic metabolism |
| Â | Target organ toxicology |
| Â | Teratology/Teratogenesis/Reproductive toxicology |
| Â | Genotoxicity/Cancer-causing agents |
| Â | Poisons/Chemical warfare/Pesticides |
| Â | Venoms/Biological warfare |
| Â | Poisonous plants |
| Â | Environmental toxicology/Environmental pollutants |
| Â | Adverse drug reactions/Idiosyncratic drug reactions |
| Â | Drug interactions |
| Â | Pharmacoepidemiology/Epidemiology |
Drug design and development | Drug discovery/design and development |
| Â | Molecular modelling/Computer-aided drug design |
| Â | Structure-activity relations |
| Â | Research methods in Pharmacology (pre-clinical) |
| Â | Intellectual property commercialisation in Pharmaceuticals |
| Â | Clinical trials |
| Â | Pharmacoeconomics |
| Â | How drugs reach the market/Drug registration |
| Â | Therapeutic drug monitoring/Regulatory affairs/Drug laws |
Neuropharmacology | Autonomic nervous system |
| Â | Cholinergics (parasympathetic/neuromuscular junction) |
| Â | Adrenergics (sympathetic) |
| Â | Autacoids (Histamine, 5-HT, Eicosanoids) |
| Â | Central nervous system |
| Â | Neuropeptides, proteins and purines (cannabinoids, purines, endogenous opioids, NPY, substance P, etc.) |
| Â | Neurotransmitters (catecholamines, indoleamines, amino acids, ACh, etc.) |
| Â | Neuroendocrinology |
| Â | Schizophrenia/Antipsychotics |
| Â | Mood/Depression/Antidepressants/Mood stabilisers |
| Â | Anxiolytics/Sedatives/Hypnotics |
| Â | Epilepsy/Seizures/Antiepileptics/Anticonvulsants |
| Â | Dementia/Drugs for dementia/Drugs for cognition |
| Â | Motor control/Movement disorders/Drugs for movement disorders |
| Â | Neurodevelopment/Neurodegeneration |
| Â | Multiple sclerosis (and demyelinating diseases)/Drugs for multiple sclerosis (and demyelinating diseases) |
| Â | Neuroprotective agents |
| Â | Excitotoxicity |
| Â | Arousal and stimulants/Drugs for ADHD |
| Â | Behavioural neuropharmacology/Psychopharmacology |
| Â | Mydriatics/Miotics |
Respiratory drugs | Drugs for asthma (bronchodilators, corticosteroids, LT antagonists, cromolyns etc.) |
| Â | Antitussives |
| Â | Drugs for COPD |
Cardiovascular and renal drugs | Drugs for hypertension |
| Â | Drugs for heart failure |
| Â | Drugs for dyslipidaemia/hypercholesterolaemia |
| Â | Drugs for angina/Myocardial infarction |
| Â | Drugs for cardiac arrhythmias |
| Â | Anticoagulants/Antiplatelet drugs/Thrombolytics/Fibrinolytics |
| Â | Diuretics |
Gastrointestinal drugs | Drugs for dyspepsia, reflux and peptic ulcers |
| Â | Drugs affecting gastrointestinal motility |
| Â | Antinauseants/Antiemetics |
| Â | Drugs for inflammatory bowel disease |
Musculoskeletal drugs | Drugs for gout and hyperuricaemia |
| Â | Drugs affecting bone and calcium metabolism |
| Â | Treatment of osteoporosis |
Metabolic/endocrine/genital drugs | Antidiabetics/oral hypoglycaemics |
| Â | Drugs for fertility/Contraception |
| Â | Anti-oestrogens/Anti-progestogens |
| Â | Drugs for labour/Uterine drugs |
| Â | Corticosteroids/Drugs for adrenal disorders |
| Â | Androgens and anabolic steroids |
| Â | Drug treatment of impotence and prostate disease |
| Â | Hormone replacement therapy/Oestrogens |
| Â | Thyroid and antithyroid drugs |
| Â | Drugs for obesity, energy balance and appetite |
| Â | Drugs for pituitary disorders |
Chemotherapy | Antibacterials |
| Â | Antivirals |
| Â | Anthelminthics/Antiprotozoals |
| Â | Antifungals |
| Â | Cancer/Neoplasia |
| Â | Cancer chemotherapy |
Analgesia/Anaesthesia/Anti-inflammatories | Nociception/Pain mechanisms |
| Â | Local anaesthetics |
| Â | General anaesthetics |
| Â | Opioid analgesics |
| Â | Migraine/Drugs for migraine |
| Â | Inflammation |
| Â | Steroidal anti-inflammatories |
| Â | Nonsteroidal anti-inflammatories and paracetamol |
| Â | Immunosuppressants/DMARDs |
| Â | Drugs for hay fever/anaphylaxis/antihistamines |
| Â | Neuromuscular blockers |
Complementary medicines | Plant-sourced drugs |
| Â | Complementary medicines |
| Â | Herbal medicines |
| Â | Foods and beverages as drugs |
Future therapies | Gene therapy/RNA therapies |
| Â | Antibody therapies |
Drugs of abuse | Addiction/Drug dependence |
| Â | Drugs of abuse (Cocaine, LSD, MDMA, Cannabis, Heroin, Alcohol, BZs etc.) |
| Â | Pharmacological management of addiction |
| Â | Drugs in sport |
| Â | Nootropic agents |
Miscellaneous | Drugs for liver disease |
| Â | Ethics |
| Â | Drugs for eczema, psoriasis and acne |
| Â | Drugs for anaemia |
| Â | Information sources about drugs |
| Â | Equity of access to drugs |
| Â | Drugs and the oral cavity |
| Â | Prescription writing and the PBS |
| Â | Other (as specified by participants) |
| Â | - statistics |
| Â | - communication skills |
| Â | - free radicals and cell damage |
| Â | - social aspects of drug abuse |
| Â | - medication management |
| Â | - medication safety |
| Â | - polypharmacy |
| Â | - legal issues |
| Â | - drug advertising |